Sheri L. Holmen
Professor
Department of Oncological Sciences
Huntsman Cancer Institute
United States of America
Biography
Sheri Holmen, PhD, is a Huntsman Cancer Institute (HCI) investigator and member of the Cell Response and Regulation Program. She is an Associate Professor in the Department of Surgery at the University of Utah School of Medicine, as well as an Adjunct Professor in the Department of Oncological Sciences.The Holmen Lab aims to define critical targets in cancer cells that can become the focus for therapeutic intervention. Because of the high cost of developing new therapies, it is essential to first identify which genetic alterations can be targeted productively. Current efforts utilize a genetic approach to address this question in tumors that are generally refractory to conventional therapies, including metastatic melanoma and glioblastoma. Identified targets are being further validated using pharmacological inhibitors of clinical importance such that laboratory findings can be quickly translated to the clinic.Dr. Holmen earned her bachelor's and master’s degrees from Western Michigan University followed by a PhD degree from the Mayo Clinic College of Medicine. Her postdoctoral research was performed in the Laboratory of Cell Signaling and Carcinogenesis at the Van Andel Research Institute.
Research Interest
Glioma Melanoma Mouse Models of Cancer Virology Oncogenes Genes, Tumor Suppressor
Publications
-
Jenkins NC, Jung J, Liu T, Wilde M, Holmen SL, Grossman D (2013). Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions. J Invest Dermatol, 133(4), 1043-51.
-
Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M (2013). Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell Melanoma Res, 26(4), E8-E14.
-
Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, Vanbrocklin MW (2013). Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss. Genes Cancer, 4(11-12), 476-85.
-
Cohen AL, Holmen SL, Colman H (2013). IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep, 13(5), 345.
-
Joshi S, Wels C, Beham-Schmid C, Fukunaga-Kalabis M, Holmen SL, Otte M, Herlyn M, Waldhoer M, Schaider H (2015). Galpha13 mediates human cytomegalovirus-encoded chemokine receptor US28-induced cell death in melanoma. Int J Cancer, 137(6), 1503-8.
